Eaton Financial Holdings’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-3,785
Closed -$276K 184
2023
Q3
$276K Sell
3,785
-148
-4% -$11.8K 0.07% 145
2023
Q2
$327K Sell
3,933
-220
-5% -$18.4K 0.25% 45
2023
Q1
$317K Sell
4,153
-1,287
-24% -$107K 0.25% 44
2022
Q4
$452K Buy
+5,440
New +$440K 0.39% 41

Other funds holding XBI

Eaton Financial Holdings's XBI Position: Q4 2023 in Review

Eaton Financial Holdings sold out of State Street SPDR S&P Biotech ETF (XBI) in Q4 2023, closing a stake of 3,785 shares — an estimated $276K sold.

Eaton Financial Holdings first reported a position in XBI in Q4 2022 and held it in 4 quarters. The position peaked at $452K in Q4 2022. 745 funds tracked by Wall St. Rank hold XBI as of Q4 2023.

  • Eaton Financial Holdings reported no remaining State Street SPDR S&P Biotech ETF position as of Q4 2023 after selling out during the quarter.
  • Eaton Financial Holdings sold 3,785 State Street SPDR S&P Biotech ETF shares in Q4 2023, an estimated $276K.
  • Eaton Financial Holdings first reported a position in State Street SPDR S&P Biotech ETF in Q4 2022 and held it in 4 quarters.
  • Eaton Financial Holdings's State Street SPDR S&P Biotech ETF position peaked at $452K in Q4 2022.
  • 745 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q4 2023.

Based on Eaton Financial Holdings's 13F filing for Q4 2023, filed 12 Feb 2024.